As of March 31, 2025, Kymera had $775 million in cash, cash equivalents and investments. Kymera expects that its cash and cash equivalents will provide the Company with a cash runway into the first half of 2028, beyond multiple clinical inflection points in our pipeline.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- KYMR Upcoming Earnings Report: What to Expect?
- Kymera Therapeutics to unveil new oral development candidate
- Kymera Therapeutics announces first patient dosed in BROADEN Phase 1b trial
- Kymera Therapeutics appoints Goodman as Chief Business Officer
- Cautious Hold Rating on Kymera Therapeutics Amid Promising KT-621 Prospects and Strategic Developments